| Literature DB >> 23525434 |
Jeremy P Langrish1, Jon Unosson, Jenny Bosson, Stefan Barath, Ala Muala, Scott Blackwell, Stefan Söderberg, Jamshid Pourazar, Ian L Megson, Andrew Treweeke, Thomas Sandström, David E Newby, Anders Blomberg, Nicholas L Mills.
Abstract
BACKGROUND: Diesel exhaust inhalation causes cardiovascular dysfunction including impaired vascular reactivity, increased blood pressure, and arterial stiffness. We investigated the role of nitric oxide (NO) bioavailability in mediating these effects. METHODS ANDEntities:
Mesh:
Substances:
Year: 2013 PMID: 23525434 PMCID: PMC3603248 DOI: 10.1161/JAHA.112.004309
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Baseline Characteristics of Study Participants
| Baseline Characteristics | Study 1: Forearm Study (n=16) | Study 2: Systemic l‐NMMA (n=14) |
|---|---|---|
| Age, y (median, range) | 23 (21 to 27) | 26 (23 to 34) |
| Male/Female | 9 (56%)/7 (44%) | 8 (57%)/6 (43%) |
| Use of oral contraceptive (female) | 5 (72%) | 3 (50%) |
| Height, cm | ||
| All | 176±9 | 178±11 |
| Male | 181±7 | 186±6 |
| Female | 169±6 | 167±5 |
| Weight, kg | ||
| All | 72±13 | 74±14 |
| Male | 80±11 | 85±6 |
| Female | 60±4 | 60±3 |
| BMI, kg/m2 | ||
| All | 23.1±2.8 | 23.2±2.1 |
| Male | 24.6±2.8 | 24.6±1.4 |
| Female | 21.2±1.0 | 21.5±1.5 |
Data expressed as mean±standard deviation unless otherwise stated. l‐NMMA indicates NG‐monomethyl‐l‐arginine; BMI, body mass index.
Plasma Concentrations of NOS Substrates and Endogenous NOS Inhibitors
| Parameter | Exposure | Baseline | 2 Hour | 6 Hour | ||
|---|---|---|---|---|---|---|
| Time | Exp | |||||
| l‐Arginine, μmol/L | Air | 74.1±16.3 | 61.6±17.8 | 59.3±10.6 | 0.006 | 0.006 |
| Diesel | 67.7±13.4 | 58.2±10.0 | 54.6±10.3 | |||
| l‐Homoarginine, μmol/L | Air | 1.75±0.46 | 1.66±0.48 | 1.70±0.51 | 0.913 | 0.412 |
| Diesel | 1.67±0.51 | 1.63±0.48 | 1.69±0.53 | |||
| ADMA, μmol/L | Air | 0.52±0.08 | 0.44±0.09 | 0.51±0.07 | 0.010 | 0.374 |
| Diesel | 0.51±0.05 | 0.44±0.06 | 0.50±0.07 | |||
| SDMA, μmol/L | Air | 0.43±0.06 | 0.41±0.07 | 0.43±0.05 | 0.451 | 0.449 |
| Diesel | 0.41±0.05 | 0.41±0.05 | 0.43±0.05 | |||
Plasma concentrations of endogenous NOS inhibitors and NOS substrates at baseline, 2 and 6 hours after the exposure during Study 1 (local l‐NMMA administration). All data expressed as mean±standard deviation. P‐values from 2‐way repeated measures ANOVA. NOS indicates nitric oxide synthase; ADMA, asymmetric dimethylarginine; SDMA, symmetric dimethylarginine.
Figure 1.A, Forearm blood flow response during infusion of l‐NMMA (2‐way repeated measures ANOVA: P=0.559 for exposure). B, Forearm blood flow during infusion of the vasodilators acetylcholine and sodium nitroprusside (2‐way repeated measures ANOVA: P=0.209 and P=0.613, respectively, for exposure). Data expressed as mean±SEM. l‐NMMA indicates NG‐monomethyl‐l‐arginine; ANOVA, analysis of variance; SEM, standard error of the mean.
Baseline Hemodynamic and Biochemical Parameters Prior to Exposure for the Systemic Administration of l‐NMMA Study
| Parameter | Air | Diesel |
|---|---|---|
| Heart rate, bpm | 67±13 | 65±8 |
| Systolic blood pressure, mm Hg | 124±12 | 124±16 |
| Diastolic blood pressure, mm Hg | 70±6 | 70±6 |
| Mean arterial pressure, mm Hg | 88±6 | 88±8 |
| Pulse wave velocity, m/s | 5.8±0.6 | 5.8±0.5 |
| Augmentation index (AIx), % | −3±9 | 1±10 |
| AIx75, % | −8±9 | −6±11 |
| Augmentation pressure, mm Hg | −1±4 | 0±4 |
| Time to wave reflection, ms | 164±20 | 172±38 |
| Cardiac index, L/min per m2 | 4.8±0.8 | 5.0±0.8 |
| Stroke index, mL/beat per m2 | 76±12 | 81±17 |
| PVRI, dynes.min/cm5 per m2 | 91±20 | 88±26 |
| Hemoglobin, g/dL | 144±14 | 140±12 |
| Hematocrit, % | 41±2 | 41±3 |
| White cell count, ×109/L | 5.9±0.9 | 5.5±0.8 |
| Neutrophil count, ×109/L | 3.1±0.8 | 2.7±0.7 |
| Monocyte count, ×109/L | 0.5±0.2 | 0.5±0.1 |
| Lymphocyte count, ×109/L | 2.0±0.3 | 2.1±0.4 |
| Platelet count, ×109/L | 224±38 | 226±33 |
| Blood urea nitrogen, mg/dL | 16.8±7.6 | 16.8±7.6 |
| Creatinine, mg/dL | 0.85±0.16 | 0.85±0.16 |
| Sodium, mmol/L | 141±1 | 141±1 |
| Potassium, mmol/L | 4.3±0.3 | 4.2±0.3 |
| TCO2, mmol/L | 28±3 | 28±2 |
| eGFR, mL/min per 1.73 m2 | 121±26 | 122±26 |
Data expressed as mean±standard deviation. l‐NMMA indicates NG‐monomethyl‐l‐arginine; bpm, beats per minute; AIx, augmentation index corrected for a heart rate of 75 bpm; PVRI, peripheral vascular resistance index; TCO2, total carbon dioxide; eGFR, estimated glomerular filtration rate.
Figure 2.Changes in invasive mean arterial blood pressure, central arterial stiffness (PWV), cardiac index, and stroke volume following systemic infusion of l‐NMMA. Data expressed as mean±SEM and composite area under the curve with 2‐way repeated measures ANOVA for exposure. PWV indicates pulse‐wave velocity; l‐NMMA, NG‐monomethyl‐l‐arginine; SEM, standard error of the mean; ANOVA, analysis of variance.